-
IUPAC Name:(2R,3S,6E,11R,15S,17R)-6-{[bis(prop-2-en-1-yl)amino]methylidene}-8-hydroxy-3-(methoxymethyl)-2,15-dimethyl-5,9,14-trioxo-4-oxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-1(10),7-dien-17-yl acetate
Supplier Lead time Price, € Pack Angene USShips from: United StatesTo:10 days 385 Description: PX-866; CAS: 502632-66-8Key Organics Limited (BIONET)Ships from: United KingdomTo:10 days 6245 mgBiosynthShips from: United KingdomTo:30 days 3785 mgDescription: PX 866; CAS: 502632-66-8For a custom pack size or bulk
please drop us a line:Enquire -
![]()
-
IUPAC Name:(2S,3S,6E,11R,15S,17R)-6-{[bis(prop-2-en-1-yl)amino]methylidene}-3-(methoxymethyl)-2,15-dimethyl-5,8,9,14-tetraoxo-4-oxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-1(10)-en-17-yl acetate
Supplier Lead time Price, € Pack Apollo ScientificShips from: United KingdomTo:TBD POA1 gDescription: CAS: 502632-66-8Apollo Scientific USAShips from: United StatesTo:TBD POA1 gDescription: CAS: 502632-66-8For a custom pack size or bulk
please drop us a line:Enquire -
![]()
-
IUPAC Name:(2R,3S,6E,11R,14S,15S,17R)-6-({[3-(dimethylamino)propyl](methyl)amino}methylidene)-8,14-dihydroxy-3-(methoxymethyl)-2,15-dimethyl-5,9-dioxo-4-oxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-1(10),7-dien-17-yl acetate
Supplier Lead time Price, € Pack MedChemExpressShips from: United StatesTo:30 days 190 Description: Names: PI3K-IN-11; Product Description: PI3K-IN-11 (compound 13) is a PI3K inhibitor, which selectively inhibits PI3Kα, PI3Kβ, PI3K, and PI3Kδ ( IC 50 s=6.4, 13, 8, and 11 nM, respectively) over mTOR ( IC 50 =2.9 μM). PX-13-17OH is greater than 420-fold selective for PI3K in a panel of 20 lipid and protein kinases. PX-13-17OH inhibits phosphorylation of Akt and S6 kinase (S6K) in PTEN-negative U87MG cells when used at concentrations ranging from 0.03 to 1 μg/mL. It inhibits tumor growth in a U87MG mouse xenograft model when administered at doses ranging from 2.5 to 10 mg/kg.; Target: PI3K; CAS: 884539-95-1MedChemExpress EUShips from: SwedenTo:30 days 200 Description: Names: PI3K-IN-11; Product Description: PI3K-IN-11 (compound 13) is a PI3K inhibitor, which selectively inhibits PI3Kα, PI3Kβ, PI3K, and PI3Kδ (IC50s=6.4, 13, 8, and 11 nM, respectively) over mTOR (IC50=2.9 μM). PX-13-17OH is greater than 420-fold selective for PI3K in a panel of 20 lipid and protein kinases. PX-13-17OH inhibits phosphorylation of Akt and S6 kinase (S6K) in PTEN-negative U87MG cells when used at concentrations ranging from 0.03 to 1 μg/mL. It inhibits tumor growth in a U87MG mouse xenograft model when administered at doses ranging from 2.5 to 10 mg/kg.; Target: PI3K; CAS: 884539-95-1Targetmol Chemicals IncShips from: United StatesTo:TBD POA1 mgDescription: PX-13-17OH has a wide range of applications in life science related research.; CAS: 884539-95-1For a custom pack size or bulk
please drop us a line:Enquire -
![]()
-
IUPAC Name:(2R,3S,6E,11R,14S,15S,17R)-17-(acetyloxy)-6-({[3-(dimethylamino)propyl](methyl)amino}methylidene)-8-hydroxy-3-(methoxymethyl)-2,15-dimethyl-5,9-dioxo-4-oxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-1(10),7-dien-14-yl (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl octanedioate
Supplier Lead time Price, € Pack MedChemExpressShips from: United StatesTo:30 days 622 Description: Names: Wortmannin-Rapamycin Conjugate 1; Product Description: Wortmannin-Rapamycin Conjugate 1 (compound 7c) is a furan ring-opened derivative of wortmannin-rapamycin conjugate with potent antitumor activities and a fine water solubility. Wortmannin-Rapamycin Conjugate 1 can inhibit the AKT phosphorylation in the tumor and can be used for cancer research .; Target: Akt; CAS: 1067892-47-0MedChemExpress EUShips from: SwedenTo:30 days 655 Description: Names: Wortmannin-Rapamycin Conjugate 1; Product Description: Wortmannin-Rapamycin Conjugate 1 (compound 7c) is a furan ring-opened derivative of wortmannin-rapamycin conjugate with potent antitumor activities and a fine water solubility. Wortmannin-Rapamycin Conjugate 1 can inhibit the AKT phosphorylation in the tumor and can be used for cancer research; Target: Akt; CAS: 1067892-47-0For a custom pack size or bulk
please drop us a line:Enquire -
![]()
-
IUPAC Name:(2R,3S,6E,11R,14S,15S,17R)-17-(acetyloxy)-6-({[3-(dimethylamino)propyl](methyl)amino}methylidene)-8-hydroxy-3-(methoxymethyl)-2,15-dimethyl-5,9-dioxo-4-oxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-1(10),7-dien-14-yl (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16Z,18R,19R,21R,23S,24Z,26Z,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl octanedioate
Supplier Lead time Price, € Pack Targetmol Chemicals IncShips from: United StatesTo:TBD POA1 mgDescription: Phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) act synergistically in promoting cancer. Wortmannin is a potent inhibitor of PI3K enzymes, while rapamycin blocks mTOR Complex 1 TORC1. Wortmannin-rapamycin conjugate consists of analogs of 17-hydroxy wortmannin and rapamycin conjugated via a prodrug linker. Hydrolysis of the prodrug linker in vivo releases the inhibitors. The wortmannin-rapamycin conjugate inhibits the growth of HT-29 colon tumors and A498 renal tumors in mice better than rapamycin alone. Also, the conjugate, when given in combination with the VEGF-blocker bevacizumab, produces substantial regression of larger A498 tumors. Finally, the wortmannin-rapamycin conjugate is tolerated better than an equivalent mixture of the inhibitors.; CAS: 1067892-47-0For a custom pack size or bulk
please drop us a line:Enquire -
![]()
